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A number of studies demonstrated a rapid onset of an antidepressant effect of non-
competitive N -methyl-D-aspartic acid receptor (NMDAR) antagonists. Nonetheless, its
therapeutic potential is rather limited, due to a high coincidence of negative side-effects.
Therefore, the challenge seems to be in the development of NMDAR antagonists dis-
playing antidepressant properties, and at the same time maintaining regular physiological
function of the NMDAR. Previous results demonstrated that naturally occurring neuros-
teroid 3α5β-pregnanolone sulfate shows pronounced inhibitory action by a use-dependent
mechanism on the tonically active NMDAR. The aim of the present experiments is to find
out whether the treatment with pregnanolone 3αC derivatives affects behavioral response
to chronic and acute stress in an animal model of depression. Adult male mice were used
throughout the study. Repeated social defeat and forced swimming tests were used as
animal models of depression.The effect of the drugs on the locomotor/exploratory activity
in the open-field test was also tested together with an effect on anxiety in the elevated
plus maze. Results showed that pregnanolone glutamate (PG) did not induce hyperlocomo-
tion, whereas both dizocilpine and ketamine significantly increased spontaneous locomotor
activity in the open field. In the elevated plus maze, PG displayed anxiolytic-like properties.
In forced swimming, PG prolonged time to the first floating. Acute treatment of PG dis-
inhibited suppressed locomotor activity in the repeatedly defeated group-housed mice.
Aggressive behavior of isolated mice was reduced after the chronic 30-day administration
of PG. PG showed antidepressant-like and anxiolytic-like properties in the used tests, with
minimal side-effects. Since PG combines GABAA receptor potentiation and use-dependent
NMDAR inhibition, synthetic derivatives of neuroactive steroids present a promising strat-
egy for the treatment of mood disorders.
Highlights:
- 3α5β-pregnanolone glutamate (PG) is a use-dependent antagonist of NMDA receptors.
- We demonstrated that PG did not induce significant hyperlocomotion.
- We showed that PG displayed anxiolytic-like and antidepressant-like properties.
Keywords: depression, anxiety, NMDA channel blocker, neuroactive steroid, 3α5β-pregnanolone glutamate
INTRODUCTION
Depressive disorders are among the most common and the most
disabling mental diseases. There exist various and widely used anti-
depressants; however, one of their major limitations is a relatively
Abbreviations: ACTH, adrenocorticotropic hormone; β-CD, hydroxypropyl-β-
cyclodextrin; CNS, central nervous system; CRH, corticotropin-releasing hormone;
DHEA/S, dehydroepiandrosterone sulfate; GABA, γ-aminobutyric acid; HPA axis,
hypothalamic–pituitary–adrenal axis; MK-801, dizocilpine; NMDA, N -methyl-d-
aspartic acid; NMDAR,N -methyl-d-aspartic acid receptor; PG, 3α5β-pregnanolone
glutamate; SSRI, selective serotonin reuptake inhibitor.
long onset of antidepressant effect. But several studies demon-
strate antidepressant properties of a single administration of ket-
amine – the non-competitive N -methyl-d-aspartic acid receptor
(NMDAR) antagonist (Berman et al., 2000; Zarate et al., 2006,
2012; Diazgranados et al., 2010). Both subjective and objective
evaluation of the mood after ketamine administration showed a
significant improvement of the mood in the interval spanning
from 2 h to 7 days (Entsuah et al., 2001; Thase et al., 2005). The
minimum treatment of 2–4 weeks (often even more) is required to
produce significant improvement in symptomatology with com-
mon antidepressants (Lam, 2012), while an infusion of ketamine
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to pharmaco-resistant patients show a similar effect (Murrough
et al., 2013). The current hypothesis for the mechanism of ket-
amine action focuses on a complex cascade of neurochemical
events that are induced by ketamine administration. These con-
sequences persist for days after the ketamine elimination. First
of all, ketamine administration blocks NMDAR. In all the cases,
the protracted antidepressant effect is mediated by the con-
sequent neuroplastic alterations (see Browne and Lucki, 2013;
Hayley and Litteljohn, 2014).
It has been more than 20 years since the first proof of anti-
depressant action of the NMDAR antagonist emerged (Trullas
and Skolnick, 1990). Since then, a growing number of evidence
confirms that glutamate neurotransmission plays a crucial role
in the neuropathology of the depression. Researchers have found
that various types of drugs impairing NMDAR functioning (com-
petitive, non-competitive and uncompetitive antagonists, and
allosteric modulators) display antidepressant effects in the pre-
clinical (Layer et al., 1995; Rogóz et al., 2002; Li et al., 2011;
Burgdorf et al., 2013; Lapidus et al., 2013; Pilc et al., 2013) as
well as in the clinical trials (Zarate et al., 2006, 2012). However, the
clinical use of NMDA antagonists in pharmacotherapy of mood
disorders is hampered by severe side-effects, particularly by psy-
chotic symptoms in humans (Krystal et al., 1994). For this reason,
research of the NMDA antagonists is a prominent topic in current
neurobiology of the depressive disorder. It focuses on the eluci-
dation of mechanisms of their antidepressant effect, and on the
development of novel antidepressants – drugs with antidepres-
sant properties and minimal side-effects, i.e., with more favorable
benefit/risk ratio.
Therefore, the research and development of the novel thera-
peutics based on the NMDA antagonists is necessary in order to
avoid psychotomimetic effects. These negative behavioral effects
are most pronounced in the case of non-competitive antago-
nists. Conversely, the behavioral side-effects of the uncompet-
itive antagonists (antagonists selective for NMDAR containing
a NR2B subunit or NMDAR glycine binding site antagonists)
are less severe (Danysz et al., 1998; Popik et al., 1998; Karcz-
Kubicha et al., 1999; Parsons, 2001; Kemp and McKernan, 2002;
Chen and Lipton, 2006).
Neurosteroids are involved in several CNS physiological and
pathological processes, such as the response to stress, depression,
anxiety, sleep, or memory deficit (see more Morrow, 2007). Anti-
depressant effects of neuroactive steroids were described in animal
models (Urani et al., 2001) as well as in patients (Wolkowitz et al.,
1997, 1999). It has been shown that antidepressant treatment nor-
malized the imbalance of 3α and 3β pregnanolone in patients
suffering from depression (Romeo et al., 1998; Schüle et al.,
2011). During social isolation, an animal model of depression-like
behavior, biosynthesis of pregnanolone is significantly decreased
(Pinna et al., 2008). SSRI are able to reverse the decreased
brain pregnanolone level, and to correct behavioral deficits
(Pinna et al., 2006).
The neurosteroids are known for their potentiation as well
as inhibition of NMDA and GABA receptors. Naturally occur-
ring 3α5β-pregnanolone sulfate has a substantial inhibitory
activity (Irwin et al., 1994; Weaver et al., 2000; Kussius
et al., 2009) on tonically activated NMDAR (Petrovic et al.,
2005). Therefore, we introduced the development and testing
of a novel synthetic NMDA antagonists derived from the
3αC pregnanolone having improved pharmacokinetic properties
(Rambousek et al., 2011).
The newly synthesized neuroactive steroid 3α5β-pregnanolone
glutamate (PG) is a representative member of a group of the
steroids exerting effects on GABAA, AMPA, kainate, and NMDAR.
Concerning the NMDAR, the mechanism of an action is not fully
understood in detail, but it can be stated that it displays specific
properties. The drug is an allosteric inhibitor of the NMDAR.
Its degree of inhibition of the NMDAR currents is independent
of the cell membrane potential. On the other hand, the binding
to its inhibitory binding site is pre-conditioned by the activation
of NMDAR by agonists. Therefore, it is so-called a use-dependent
allosteric inhibitor of NMDAR (see Korinek et al., 2011) with more
potent inhibition of responses mediated by NR1/NR2C-D recep-
tors, compared to those mediated by the NR1/NR2A-B receptors
(Petrovic et al., 2005) and GABAA agonist (unpublished data). On
the contrary to the non-competitive NMDA antagonists, 3α5β-
PG is devoid of its adverse side-effects. 3α5β-PG binds only to
the extrasynaptic and tonically activated NMDAR, which results
in use-dependent selectivity (Rambousek et al., 2011).
In the present study, we examined potential antidepressant
activity of PG. The effect of a single dose administration of PG
was assessed by the Porsolt forced swim test, and by the repeated
stress of social defeat, both used as common animal models of
depression. The locomotor activity and the anxiolytic properties
of PG were evaluated together with an open field and elevated
plus maze tests. The effect of the chronic administration of PG
on the aggressive behavior of singly housed male mice was eval-
uated by paired agonistic interactions with the non-aggressive
group-housed partners.
MATERIALS AND METHODS
ANIMALS
Open field, elevated plus maze, and forced swimming studies
Naive adult male ICR mice (VELAZ s.r.o.,Prague,Czech Republic),
15 weeks old and weighing 25–35 g, were used for the experiments.
The animals were housed in groups of five in the plastic cages in
a keeping of Institute of Physiology, Academy of Sciences of the
Czech Republic. The mice had ad libitum access to the laboratory
chow and water, except during behavioral experiments, and they
were kept in a regulated environment (22°C, 50% humidity) under
a 12-h light/dark cycle (lights on at 06:00 a.m.).
Social defeat and agonistic interaction studies
Naive adult male mice (ICR strain, VELAZ s.r.o., Prague, Czech
Republic, 30–37 g) were used in this study. Food and water were
available ad libitum. Mice were housed in a keeping of Depart-
ment of Pharmacology, Faculty of Medicine of Masaryk University,
Brno, either individually without any handling in self-cleaning
cages with a grid floor (8 cm× 6 cm× 13 cm), or in groups of
17–20 in standard plastic cages (38 cm× 22 cm× 14 cm) with the
floors covered with wooden shavings. The animals were housed,
and behavioral testing was performed in a different room during
the light phase of the constant light–dark cycle, with lights on at
06:00 and off at 18:00 h. The temperature was maintained at 21°C,
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and relative humidity was 50%. The group-housed mice were not
handled, except on the experimental days. Singly housed mice were
handled after 3 weeks of isolation, just during oral administration
of PG.
Experiments were carried out between 09:00 a.m. and 06:00
p.m. All animal procedures were conducted in accordance with
the European Community Council Directives of November 24,
1986 (86-609/EEC), and the Decree of October 20, 1987 (87–848).
The study protocol was approved by the Animal Care Committee
of the Institute of Physiology of Academy of Sciences of the Czech
Republic and Masaryk University Brno,Faculty of Medicine,Czech
Republic.
DRUG ADMINISTRATION
Drugs and chemicals used in the study were purchased from
Sigma-Aldrich (Germany). PG was prepared by the esterification
of 3α-hydroxy-5β-pregnan-20-one (Steraloids Inc., USA) with a
protected glutamic acid. The synthesis is thoroughly described in
Rambousek et al. (2011). PG solutions were prepared by dissolu-
tion of PG in hydroxypropyl-β-cyclodextrin (β-CD, 72 mM saline
solution, pH adjusted to 7.4 by 1 M NaOH). MK-801 and ketamine
were prepared by dissolution in saline. β-CD was administered as
a control for PG, and saline as a control for dizocilpine (MK-801)
and ketamine. Dizocilpine was used as a representative of non-
competitive highly selective NMDA antagonists. In addition, keta-
mine was used as a non-competitive NMDA antagonist possessing
antidepressant activity. In the open-field test, PG was applied i.p.
at doses of 0.1, 1, and 10 mg/kg, and dizocilpine at the dose of
0.3 mg/kg, and ketamine at the dose of 10 mg/kg. In the elevated
plus maze test, PG was injected i.p. at doses of 1 and 10 mg/kg. In
the forced swim test, PG was administered i.p. at doses of 0.1, 1,
and 10 mg/kg, and in the social defeat test and agonistic interac-
tions orally at the dose of 1 mg/kg via gastric tube. In these tests, PG
was administered 30 min prior to behavioral testing at a volume of
1 ml/kg, except for the social defeat test and agonistic interactions,
where PG was administered 60 min prior to testing. In agonis-
tic interactions, PG at the dose of 1 mg/kg/day was administered
orally once daily for 30 days at a volume of 1 ml/kg. All animals
received the same volume of liquid per 1 kg of body weight.
BEHAVIORAL PROCEDURES
Open-field test
The animals were placed individually into a circular open-field
arena (82 cm in diameter), located in a soundproof room. The
locomotor activity in the open field was assessed by placing the ani-
mal in the arena immediately after i.p. application of PG, MK-801,
ketamine, and their vehicles, and monitoring their activity over
50 min using a video tracking system (iTrack, Biosignal Group,
USA). We analyzed the locomotor activity, expressed as a total dis-
tance traveled (Figure 1). The number of animals per group was
as follows: five animals in ketamine, MK-801 and PG 10 mg/kg
group, seven mice in PG 0.1 mg/kg group, eight mice in saline and
PG 1 mg/kg group, and nine mice in β-CD group.
Elevated plus maze
The apparatus consisted of open arms (30 cm× 6.5 cm), crossed
at right angles, with two arms of the same length enclosed by
walls of 15.5 cm high (closed arms). The whole apparatus was
FIGURE 1 | Locomotor activity in the open field was assessed by
placing an animal in the arena immediately after i.p. application of PG,
MK-801, ketamine, and their vehicles. Locomotor activity was monitored
over 50 min. Ketamine and dizocilpine administration resulted in
hyperlocomotion. Animals treated with these non-competitive NMDA
antagonists significantly increased distance traveled. PG administration did
not lead to significant changes in locomotion. All values represent group
means±SEM. *p<0.05 compared to the saline group.
raised 50 cm above the floor. At the beginning of each session,
the mouse was placed on the central platform (6.5 cm× 6.5 cm)
facing the closed arm. The time spent in the open, close arms,
and central platform was recorded over a 10-min test session by a
video recorder positioned above the maze, tracked, and analyzed
by software (iTrack, Biosignal Group, USA). Each experimental
group consisted of 10 mice.
Forced swimming
The forced swimming test was carried out in accordance with
the methods described by Porsolt et al. (1978), only with slight
modifications. Mice were randomly assigned into the three
groups – vehicle treated (10 mice), PG 0.1 mg/kg treated (10 mice),
PG 1 mg/kg (8 mice), and PG 10 mg/kg (8 mice) treated mice.
Each mouse was placed in a 25-cm plastic transparent cylinder
(12 cm in diameter) containing 10 cm of water at 24± 1°C. The
mice were left in the cylinder for 6 min, and their behavior was
recorded. The duration of immobility was scored in the last 4 min
of the swimming test. Mice were considered to be immobile if
they floated while making only necessary movements to keep the
head above water (Porsolt et al., 1978). In addition to immobility
duration, we analyzed time to the first floating. Latency was mea-
sured immediately after the mice were put into the water. Recorded
videos were analyzed by two independent observers, blind to the
treatment conditions. Analysis was performed by Observer 3.0
(Noldus Information Technology, The Netherlands) software, and
the results were displayed as ethograms in excel tables.
Social defeat
The chronic social defeat stress procedure was carried out using
a similar method, described by Sulcova and Krsiak (1987) and
Pistovcakova et al. (2005). In the first part of the experiment, mice
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were given β-CD (14 mice) or PG (18 mice) orally via a gas-
tric tube. Administration was carried out in a randomized order,
60 min prior to the open-field test observations performed in the
identical animal cage, but in a different room from that used
for the social defeat interactions. Each animal was placed singly
into the center of a novel environment (arena 30 cm× 30 cm)
of the PC-controlled tracking apparatus Acti-track (Panlab, S.L.,
Spain) with the infrared beam sensors. Over the 8-min test-
ing period, the overall distance traveled (as a marker of loco-
motor/exploratory behavior) in the open field was measured.
Two days later, each mouse was defeated with a singly housed
mouse exhibiting an aggressive behavior in a 4-min paired ago-
nistic interaction. The procedure was repeated four times, 7 days
apart. Immediately after the last (fourth) agonistic interaction,
each mouse was randomly assigned to the vehicle (12 mice),
or the treatment group (6 mice). Sixty minutes following the
drug administration, the animal was placed into the open-field
arena, and the overall distance traveled was measured, as described
above. Mice that received a timid partner instead of an aggres-
sive one were excluded from the experiment, since they were not
defeated.
Agonistic interactions
Prior to the experiment, mice were housed individually for
3 weeks. Each individually singly housed mouse was allowed
30 min adaptation in a Plexiglas neutral observation cage
(20 cm× 20 cm× 30 cm) with clean wood shavings before it was
coupled with a group-housed non-aggressive male partner for
4 min interaction. On the first day of the experiment, each ani-
mal received vehicle orally via a gastric tube 60 min prior to the
agonistic interaction. Singly housed mice were divided into two
groups, according to their behavior during the control interac-
tion (vehicle treatment) with the group-housed partner: (a) an
aggressive one (attacking group-housed mouse at least once), and
(b) a timid one [exhibiting no attacks, displaying defensive-escape
(timid) behavior toward the group-housed mouse]. The num-
ber, latency, and duration of attacks, tail rattles, unrests (aggressive
activities), defenses, escapes, alert postures (timid activities), social
sniffing, climbing, and following the partner (sociable behavior)
exhibited by singly housed mice were recorded and evaluated
by the hardware/software Observer 3.1, Noldus Technology, Hol-
land. Aggressive singly housed mice were subdivided into the two
groups – one receiving vehicle (9 mice) and one receiving PG
(11 mice). The agonistic interactions with group-housed mice
were video-recorded after 14 and 30 days of vehicle/drug admin-
istration. The test protocol was adopted from Sulcova and Krsiak
(1987).
STATISTICAL ANALYSIS
Data are presented as the group means± standard error of mean
(SEM). Statistical analyses were performed by the program Graph-
Pad Prism 6.0 (San Diego, CA, USA). The statistical significance
for the social defeat test was detected by the two-way ANOVA, fol-
lowed by Sidak’s post hoc test. The treatment (two factor level)
and the stress (two factor levels) served as independent vari-
ables. In the agonistic interaction test, the effect of the treatment
(two factor level) and the length of administration (three factor
levels) of PG/vehicle were assessed by the two-way repeated mea-
sures ANOVA (control interaction first day vs. interactions days
14th and 30th). In the other tests, where the treatment effect
was assessed alone, the one-way ANOVA was conducted. Sidak’s
post hoc test was used when appropriate. The significant level was
set at p< 0.05.
RESULTS
OPEN FIELD
Statistical analysis of the locomotor activity in the open field by
the one-way ANOVA showed significant differences in total dis-
tance traveled F(6, 40)= 8.034, p< 0.0001. MK-801 0.3 mg/kg
and ketamine 10 mg/kg induced hyperlocomotion (Figure 1)
during 50 min of an exploration. PG plasma levels were highest
15 min after i.p. administration, and brain neurosteroid level peaks
occurred 60 min after i.p. application (Rambousek et al., 2011).
Therefore, we chose a time interval of 30 min after i.p. application
of PG for the subsequent tests.
ELEVATED PLUS MAZE
One-way ANOVAs revealed that PG administered at the dose of
1 mg/kg significantly increased the time spent in the open arms,
F(2, 24)= 7.654, p= 0.0027 and decreased the time spent in the
central platform, F(2, 24)= 10.01, p= 0.0007. Mice treated with
PG 10 mg/kg did not display anxiolytic behavior, and their times
spent in the open arms and central platform did not differ from the
control group treated with only the vehicle. The treatment had no
effect at all on the time spent in the closed arms (Figure 2A). Time
spent in the central platform may be indicative of risk assessment
behavior. Increased time spent in the central platform may be a
sign of hesitation before entering either arm. In order to evaluate
locomotor activity in the elevated plus maze, an analysis of open to
close arms entries was conducted as well. However, no significant
difference was revealed (Figure 2B), probably due to a big variance
within each treatment group.
FORCED SWIMMING
Even though PG treatment led to the slight decrease in immobility
time (Figure 3A), none of the doses used significantly reduced the
immobility in comparison with the controls. As the next parame-
ter, we assessed the time of the first floating (latency, Figure 3B).
One-way ANOVA detected significant elongation of the latency
after PG 1 mg/kg treatment F(3, 29)= 5.248, p= 0.0051. The
discrepancy between results obtained from immobility and the
latency analyses remains to be clarified. Sensitivity of the two
parameters to antidepressant treatment may differ.
SOCIAL DEFEAT
Group-housed mice repeatedly defeated on aggressive agonistic
interactions with singly housed partners exhibited decreased loco-
motor activity in the open field. Two-way ANOVA revealed sig-
nificant effect of treatment vs. stress interaction F(1, 46)= 4.687,
p= 0.0356. No significance was found for the effect of factor stress
and factor treatment. PG 1 mg/kg administration normalized the
stress-induced inhibition of locomotor activity in the open field,
expressed as an overall distance traveled (Figure 4).
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FIGURE 2 | Anxiolytic effect of PG was assessed in an elevated plus
maze. (A) PG administered at the dose of 1 mg/kg significantly increased
the time spent in the open arms, and decreased the time spent in the
central platform. Mice treated with PG at the dose of 10 mg/kg did not
display anxiolytic behavior. All values represent group means±SEM.
*p<0.005 compared to the vehicle, β-CD group. (B) The analysis of open to
close arm entries did not reveal differences between treatment groups,
probably due to big differences in variance within each group. All values
represent group means±SEM.
AGONISTIC INTERACTIONS
Chronic administration of PG at the dose of 1 mg/kg over 30 days
reduced aggressive actions in singly housed mice exhibiting aggres-
sive behavior on the first interaction. Two-way repeated measures
ANOVA detected significant effect of the treatment vs. the length
of administration interaction in the parameter duration F(2,
116)= 5.407, p= 0.0057. Length of the administration showed
significant effect F(2, 116)= 11.97, p< 0.0001, whereas treatment
showed no influence on the duration of aggression. Aggression was
significantly reduced after 14 and 30 days of PG 1 mg/kg admin-
istration, compared to the scores of vehicle treated controls in
the first day (Figure 5A). This reduction was more pronounced
after 30 days of PG treatment (p< 0.0001 post hoc analysis), com-
pared to only 2 weeks treatment (p= 0.0037). The time spent in
aggressive interactions dropped in PG treated animals.
FIGURE 3 | In the forced swim test, we evaluated the possible
antidepressant effect of PG. (A) Immobility time in the forced swim test
was assessed 30 min after i.p. administration of PG and vehicle. None of
the doses applied significantly influenced floating. Average group
values±SEM. (B) In addition to immobility duration in the forced
swimming test, we measured time to the first floating as well.
Administration of PG at the dose of 1 mg/kg significantly prolonged the
latency to the first floating compared to controls. All values represent group
means±SEM. *p<0.005 compared to the vehicle group.
Time to the first aggressive action (the latency) was prolonged
in PG treated mice. Two-way repeated measures ANOVA revealed
the effect of the factor treatment F(1,58)= 4.55, p= 0.0372 and
the factor of administration length F(2, 116)= 8.652, p= 0.0003
on the latency. Interaction between the two factors was not sig-
nificant. It took more time for the PG treated animals to attack
the intruder after 14 and 30 days of PG application in compari-
son to the controls (Figure 5B). Again, this effect was greater after
longer administration (p< 0.0001 after 30 days vs. p= 0.0275 after
14 days, revealed by post hoc test).
The frequency of aggressive actions decreased over the course of
an experiment. Interaction between the two factors, treatment, and
length of administration, came out significant [F(2, 116)= 8.505,
p= 0.0004] when analyzed by the two-way repeated measures
ANOVA. The length of administration had a significant effect F(2,
116)= 30.04, p< 0.0001 on the frequency. The kind of treatment
we used had no effect. Frequency expressed as a number of aggres-
sive actions decreased after 14 and 30 days of PG treatment. Vehicle
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FIGURE 4 | Group-housed mice repeatedly stressed by defeat on four
agonistic interactions (7 days apart) with aggressive singly housed
partners exhibited depressed locomotor activity in the open field. This
effect was disinhibited by treatment with PG at the dose of 1 mg/kg. There
was no difference in unstressed animals between two treatment groups in
the open-field activity. All values represent group means±SEM. *p<0.05
compared to the stressed vehicle treated animals.
treated mice also showed significant reduction in the frequency of
aggressive actions between the 1st and 30th day. However, this
change in frequency was not as prominent (p= 0.0163) as in PG
treated animals (p< 0.0001 for both time intervals) (Figure 5C).
Taken altogether, mice treated daily with PG at the dose of 1 mg/kg
over the course of 30 days indulged less in aggressive interactions.
DISCUSSION
The present study focused on the evaluation of antidepressant-like
and anxiolytic-like effects of newly synthesized neurosteroid PG.
Neurosteroids are known for their neuroprotective and antipsy-
chotic effects (Pringle et al., 2003; Veiga et al., 2003; MacKenzie
et al., 2007; Rambousek et al., 2011; Vales et al., 2012), and
alternation of their brain levels is well-documented in various
neurodegenerative diseases and aging (Vallée et al., 1997; Nafziger
et al., 1998; Kim et al., 2003; Aldred and Mecocci, 2010; Luchetti
et al., 2010; Sorwell and Urbanski, 2010). Similarly, the down-
regulation of neurosteroid synthesis possibly contributes to the
development of depressive disorders and anxiety (Morrow, 2007;
Schüle et al., 2011, 2014). Neurosteroids as potent NMDAR antag-
onist and GABA receptor agonists might be promising therapeutic
agents in depressive disorders (Zorumski et al., 2013).
Our results from the open-field test indicate that hyperloco-
motion found in MK-801 and ketamine treated animals is not
present after PG application (Figure 1). It is in concordance with
our previous results (Vales et al., 2012). As opposed to non-
competitive NMDA antagonists such as dizocilpine (MK-801),
ketamine, and PCP often used for induction of schizophrenia-like
behavior (Bubeníková-Valesová et al., 2008), PG does not display
psychotomimetic properties, but quite the contrary. Adminis-
tration of PG at the doses of 0.1 and 1 mg/kg did not signifi-
cantly influence spontaneous locomotor activity in comparison
to the control (Figure 1). Furthermore, PG at the highest dose
of 10 mg/kg exhibited hypolocomotion after i.p. administration.
FIGURE 5 | In 4-min paired agonistic interactions, singly housed mice
were confronted with non-aggressive group-housed partners. Chronic
administration of PG at the dose of 1 mg/kg over 30 days reduced
aggressive behavior in singly housed mice exhibiting aggressive behavior
during the first agonistic interaction. (A) Graph shows the duration of
aggressive activities. The duration was significantly reduced after 14 and
30 days of PG 1 mg/kg administration, compared to the scores of vehicle
treated controls in the first day. The effect was more prominent after
30 days. (B) Graph shows latency to the first aggressive action. Latency
prolonged in PG treated mice after 14 and 30 days of PG application in
comparison to controls. Again this effect was greater after longer
administration. (C) Graph displays number of aggressive actions. Frequency
decreased over the course of the experiment. Vehicle treated mice also
showed significant reduction in the frequency of aggressive actions
between the 1st and 30th day. However, this change in frequency was not
as prominent as in PG treated animals. All values represent group
means±SEM. *p<0.05, **p<0.005, #p<0.0001 compared to the
vehicle treated animals on the first day of agonistic interaction.
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It cannot be interpreted as an unexpected effect, because GABA
agonists as well as NMDA antagonists are drugs, which produce
typically sedative and anesthetic effects.
The lower risk of hyperlocomotion can be explained by the
different mechanism of action. PG is a use-dependent NMDA
inhibitor, which has a more pronounced inhibitory action on the
tonically active NMDAR (Petrovic et al., 2005). The hypothesis
underlying the ability of use-dependent inhibitors to differenti-
ate between phasic physiological and tonic pathological activation
of NMDAR during pathological states have gained relatively wide
acceptance. However, it is still unclear how such compounds could
differentiate between normal and abnormal synaptic activation of
NMDAR (Borovska et al., 2012). The lowered risk of hyperloco-
motion displays memantine as well. Memantine has been shown
to result in the preferential blockade of excessive NMDAR activity,
while sparing normal excitatory synaptic function (Lipton, 2006,
2007).
Anxiolytic performance of PG was assessed in the elevated plus
maze test. Agonists of GABA receptors are recognized for their
anxiolytic properties (Brot et al., 1997), and in the elevated plus
maze test they increase the time spent in open arms (Rodgers and
Johnson, 1998). PG at the dose of 1 mg/kg exhibited anxiolytic-
like activity clearly indicated by significant increase in time spent
in open arms (Figure 2A). Anxiolytic-like properties of PG were
also previously confirmed by decreased shock-induced ultrasonic
vocalization in rats after PG application (Vales et al., 2012). The
analysis of open to close arm entries did not reveal differences
between treatment groups (Figure 2B), however the decrease in
locomotion in the PG of 10 mg/kg treated group was not as promi-
nent as in the open field. It can be explained by the decreased
habituation to the maze, since animals spent considerably less time
in the elevated plus maze than in the open field, and the activity
of the mice is enforced by the nature of the task.
Pregnenolone glutamate at all doses slightly reduced floating
when applied 30 min prior to the test, however this decrease was
not significant (Figure 3A). We analyzed not only the overall time
of floating in the session, but also the time to the first floating. In
our experiment, PG 1 mg/kg significantly prolonged the latency to
the first immobility (Figure 3B). Time to the first floating analysis
produced more robust results, at least in our experimental set-up.
According to literature available and our experience, the forced
swim test is sensitive to various independent variables, such as
mouse strains (Lucki et al., 2001; Mason et al., 2009), age of mice
used (Mason et al., 2009; Sequeira-Cordero et al., 2013), water
temperature (Pintér et al., 2011), 2 days vs. 1 day protocol, water
depth (Pintér et al., 2011), diameter of cylinders animals swim in,
seasonal changes, etc. (Petit-Demouliere et al., 2005). We probably
failed to find the optimal protocol where the differences between
the groups would be more distinct.
3α-reduced neuroactive steroids have anxiolytic and
antidepressant-like effects in the preclinical studies (Eser et al.,
2006). Even though PG meets this effect, it failed to improve immo-
bility scores in the forced swim test. Similar results were obtained
after progesterone application (Urani et al., 2001). However, the
administration of allopregnanolone significantly reduced the time
spent by immobilization (Rodríguez-Landa et al.,2009), indicating
that allopregnanolone is a more potent GABA activator, compared
to progesterone. The mechanism of action of PG on GABA neu-
rons is not fully known. If the failure to decrease immobility in
the forced swimming could be ascribed to the lower affinity of
PG to GABA receptors, or if it is caused by the methodological
drawbacks in the test, remains to be clarified.
Pregnenolone glutamate at the particular dose of 1 mg/kg had
the most pronounced effect in the tests mentioned above. There-
fore, we decided to use this concentration in the repeated social
defeat model. This animal model of depressive disorder is more
plausible than the forced swim test, since it mimics a different
aspect of depression by prolonged exposure to psychosocial stress
(Chaouloff, 2013; Venzala et al., 2013). In the social defeat test, PG
at 1 mg/kg normalized the locomotor activity in the open field in
mice exposed to aggressive conspecific prior to open-field testing
(Figure 4). Stressed mice receiving no PG exhibited stress-induced
reduction in locomotion measured by distance passed. There was
no difference in unstressed animals between the two treatment
groups in the open-field activity. The spontaneous locomotor
activity was not affected by PG administration; this conclusion
is also supported by the results from the open field.
The social defeat stress leads to depression-like abnormalities in
defeated animals, lasting for weeks, such as anxiety, social avoid-
ance, anhedonia, and changes in body weight, increased blood
pressure, suppressed immune responses, and others (Blanchard
et al., 2001; Huhman, 2006; Chaouloff, 2013). Among the most
often noted behavioral responses is the decrease in activity and
exploration in the open field (Meerlo et al., 1996; Rygula et al.,
2005; Razzoli et al., 2009). Chronic, but not acute, treatment with
antidepressants, both SSRI and tricyclics, can reverse the con-
sequences of social stress exposure (van Bokhoven et al., 2011;
Olivares et al., 2012;Venzala et al., 2012). Similarly, NMDAR antag-
onist (Jasnow et al., 2004) and GABA receptor agonist (Jasnow and
Huhman, 2001) microinjected to the amygdala block conditioned
defeat.
Aggressive mice after 30 days of single-housing were receiving
PG of 1 mg/kg chronically over 30 days. PG administration led
to the significant decrease of aggressive behavior in the agonis-
tic interactions with non-aggressive group-housed partners, when
compared to the control interaction in the first day of the exper-
iment. The duration and frequency of the aggressive behavior
decreased after 14 days of chronic application of PG. An even
more profound effect was reached after 30 days of application
(Figures 5A,C). The significant decrease in frequency was also
detected in vehicle treated animals 30 days after β-CD adminis-
tration. However, this effect was less prominent, compared to PG
treated animals (Figure 5C), and it might be caused by habituation
to intruder. The latency to the first aggressive action was prolonged
14 days after PG administration, and it was again accompanied by
a more profound effect 30 days after (Figure 5B). Taken together,
the mice treated daily with PG at the dose level of 1 mg/kg over the
course of 30 days indulged less in aggressive interactions.
Stress induced by social isolation causes a significant decrease in
pregnenolone, progesterone, allotetrahydrodeoxycorticosterone,
and allopregnanolone concentrations in the cerebral cortex, com-
pared to the group-housed controls (Serra et al., 2000). The
neuroactive steroid changes were not evident after 48 h of chronic
stress exposure, but their decrease was present 7 days after the
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chronic stress, with the most prominent change 30 days after (Serra
et al., 2000). Stress and depression are associated with a decrease
in GABAergic function in the PFC and hippocampus (Benes et al.,
2008; Croarkin et al., 2011). Administration of PG could lead to
normalization of the level of GABA potentiating neurosteroids,
and therefore contribute to the homeostasis restoration (aggres-
sion reduction/normal locomotor activity) by enhancement of the
GABA neurotransmission.
Chronic stress reduces the production of allopregnanolone,
as well as other GABAergic neurosteroids (Serra et al., 2000).
Decreased levels of neurosteroids in the plasma and CSF are found
in patients with major depression (Romeo et al., 1998; Uzunova
et al., 1998). Prolonged exposure to stress may induce a reduction
in pituitary responsiveness to high concentrations of CRH, leading
to desensitization, and consequently to decreased ACTH secretion
(Hoffman et al., 1985), affecting neurosteroid synthesis. A reduced
ACTH response to chronic stress leads to hyper-responsiveness of
the hypothalamic–pituitary–adrenal axis (HPA) axis to the new
stimuli, and confers vulnerability to mood and anxiety-related
disorders, as well as depression (Biggio and Purdy, 2001). Antide-
pressant treatment normalizes the altered allopregnanolone levels
(Uzunov et al., 1996; Uzunova et al., 1998; Schüle et al., 2014)
suggesting that GABAergic neurotransmission alteration by the
neurosteroids has a therapeutic effect.
The increasing number of evidence shows that the NMDARs
play a crucial role in the neurobiology and treatment of depres-
sion. PG as the use-dependent inhibitor of NMDARs binds only to
the extrasynaptic and tonically activated NMDARs, leaving nor-
mal neurotransmission unaffected (Rambousek et al., 2011), and
therefore causing less severe side-effects. The effect of neuroac-
tive steroids appears to be subtype selective (Gibbs et al., 2006).
Similarly, PG displays more potent inhibition of responses medi-
ated by NR1/NR2C-D receptors, compared to those mediated by
NR1/NR2A-B receptors (Petrovic et al., 2005). The current chal-
lenge in development of steroidal NMDA antagonists suitable for
clinical use is in the low potency of existing drugs. Nonethe-
less, if both the GABAA enhancers and NMDA antagonists have
antidepressant potential, the ideal agent might be the one that
combines all these effects in a single molecule (Zorumski et al.,
2013). Therefore, it might be surprising that DHEA and DHEAS
as positive NMDA and negative GABAA modulators exert antide-
pressant activity (Wolkowitz et al., 1997, 1999; Urani et al., 2001).
However, the mechanism of action of DHEA/S suggests an indirect
way of normalizing HPA axis activity (via MAP2C protein activity,
serotonin turn-over, anti-glucocorticoid effects, MAO inhibitory
effect, promotion of neurogenesis, etc.) (Maninger et al., 2009;
Pérez-Neri et al., 2009; Felice et al., 2012).
Taken altogether, these results showed that 3α5β-PG activity at
NMDARs lacks negative side-effects accompanying treatment with
non-competitive NMDA antagonists that impair normal neuro-
transmission. Since PG combines both effects – GABAA receptor
potentiation and the NMDAR inhibition – it has a potential as an
antidepressant in the treatment of depressive symptoms.
In conclusion, we demonstrated in animal models
antidepressant-like and anxiolytic-like activities of 3α5β-PG – an
analog of naturally occurring 3α5β-pregnanolone sulfate. PG is an
example of a promising neurosteroid showing possible potential
for development of a novel antidepressant, procognitive, and
neuroprotective agents. This branch of research gives rise to a
possibility of obtaining drugs with antidepressant/anxiolytic prop-
erties and minimal side-effects, i.e., with a more favorable risk/
benefit ratio.
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